Dietary recommendations for dysbetalipoproteinemia: A need for better evidence.

Martine Paquette, Chantal Blais, Andréanne Fortin, Sophie Bernard, Alexis Baass

Journal: Journal of clinical lipidology 2023;17(4):549-556

PMID: 37268489

Full Text on Elsevier Science View on PubMed

Abstract

The increased risk of cardiovascular disease in patients with dysbetalipoproteinemia (DBL) is well documented and is associated with the dysfunctional metabolism of remnant lipoproteins. Although these patients are known to respond well to lipid-lowering medication including statins and fibrates, the best dietary approach to lower remnant lipoprotein accumulation and to prevent cardiovascular outcomes remain unclear. Indeed, current evidence is based on studies published mainly in the 1970s, which comprise small sample sizes and methodological limitations. This review aims to summarize nutritional studies performed in DBL patients to date and to discuss potential avenues in this field and future areas of research.

Address: Genetic Dyslipidemias Clinic of the Montreal Clinical Research Institute, Montreal, Québec, Canada.; Genetic Dyslipidemias Clinic of the Montreal Clinical Research Institute, Montreal, Québec, Canada; Department of Medicine, Division of Endocrinology, University of Montreal, Montreal, Québec, Canada; Research Centre of the Centre Hospitalier Universitaire de Montréal (CRCHUM), Montreal, Québec, Canada.; Genetic Dyslipidemias Clinic of the Montreal Clinical Research Institute, Montreal, Québec, Canada; Department of Medicine, Divisions of Experimental Medicine and Medical Biochemistry, McGill University, Montreal, Québec, Canada. Electronic address: [email protected].

DOI: 10.1016/j.jacl.2023.05.101

Link outs

Free resources

Medical:

https://medlineplus.gov/cholesterolmedicines.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Hyperlipoproteinemia Type III, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiovascular Diseases, Lipoproteins